1159600-30-2

Upstream product

• 393165-20-3 (Z)-N-hydroxy-4-fluoro-benzenecarboximidoyl chloride 
• 954230-39-8 3-(4-fluoro-phenyl)-5-methyl-isoxazole-4-carboxylic acid ethyl ester 
• 73781-91-6 6-Chloronicotinic acid methyl ester 
• 1018297-63-6 [3-(4-fluoro-phenyl)-5-methyl-isoxazol-4-yl]-methanol 
• 1736-21-6 3-(4-fluoro-phenyl)-5-methyl-isoxazole-4-carboxylic acid 
• 459-57-4 4-fluorobenzaldehyde 
• 42202-95-9 4-fluoro-N-hydroxybenzimidoyl chloride 
• 459-23-4 4-fluorobenzaldoxime 

Downstream Products

• 1159600-32-4 6-[3-(4-fluoro-phenyl)-5-methyl-isoxazol-4-ylmethoxy]-nicotinic acid 
• 1159600-41-5 (1,1-dioxo-1λ⁶-thiomorpholin-4-yl)-{6-[3-(4-fluoro-phenyl)-5-methyl-isoxazol-4-ylmethoxy]-pyridin-3-yl}-methanone 

Relevant academic research and scientific papers

(1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV

The invention relates to an administration unit comprising a compound of formula and/or pharmaceutically acceptable salts thereof, and to a packaging comprising the administration unit according to the invention.

SOLID FORMS OF 1,L-DIOXO-4-THIOMORPHOLINYL)-[6-[[3(4-FLUOROPHENYL)-5-METHYL-4-ISOXAZOLYL]METHOXY]-3-PYRIDINYL]-METHANONE

The instant invention relates to novel solid forms of the compound of formula (I), as well as solvates, inclusion complexes with other suitable compounds, processes for their manufacture, pharmaceutical compositions containing these solid forms, and their

NOVEL SOLID FORMS

The instant invention relates to novel solid forms of the compound of formula (I) as well as solvates, inclusion complexes with other suitable compounds, processes for their manufacture, pharmaceutical compositions containing these solid forms, and their

ISOXAZOLE-PYRIDINE DERIVATIVES

The present invention is concerned with isoxazole-pyridine derivatives of formula I wherein X, R1 to R6 are as described herein. The compounds are active on the GABA A α5 receptor binding site and useful for the treatment of cognitive disorders, such as Alzheimer's disease.